CoChat

Olanzapine Augmentation in Treatment-Resistant Panic Disorder: A 12-Week, Fixed-Dose, Open-Label Trial

Sepede, Gianna, De Berardis, Domenico, Gambi, Francesco, Campanella, Daniela, La Rovere, Raffaella, D'Amico, Michele, Cicconetti, Alessandra, Penna, Laura, Peca, Silvana, Carano, Alessandro, Mancini, Enrico, Salerno, Rosa Maria, Ferro, Filippo Maria · 2006 · Journal of Clinical Psychopharmacology
Cited by 68

The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.

Abstract

The purpose of our study was to evaluate the efficacy and tolerability of low-dose olanzapine augmentation in selective serotonin reuptake inhibitor (SSRI)-resistant panic disorder (PD) with or without agoraphobia. In this 12-week, open-label study, 31 adult outpatients with treatment-resistant PD who had previously failed to respond to SSRI treatment were treated with fixed dose of olanzapine (5 mg/d) in addition to SSRI. Efficacy was assessed using the Panic Attack and Anticipatory Anxiety Scale (PAAAS), the Agoraphobic Cognitions Questionnaire (ACQ), the Hamilton Rating Scale for Anxiety (HAM-A), the Hamilton Rating Scale for Depression (HAM-D), the Global Assessment of Functioning Scale (GAF), and the Clinical Global Impression of Improvement (CGI-I). Twenty-six patients completed the trial period with a dropout rate of 16.1%. At week 12, 21 patients were responders (81.8%), and an overall improvement on all rating scales was observed in all patients both with or without agoraphobia. Fifteen patients (57.7%) achieved remission. Olanzapine was well tolerated and the most frequent adverse effects were mild-to-moderate weight gain and drowsiness. No extrapyramidal symptoms were reported. Olanzapine appears to be effective as augmentation strategy in the treatment of SSRI-resistant PD, but study limitations must be considered and placebo-controlled studies are needed.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1097/01.jcp.0000195108.01898.17

Cites

2 of 2 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 2 references

Research works printed but not linked: 19

  1. Weissman, 1997, The cross national epidemiology of panic disorder., Arch Gen Psychiatry, 54, 305, 10.1001/archpsyc.1997.01830160021003 · DOI · Paper page
  2. Sheehan, 2002, The management of panic disorder., J Clin Psychiatry, 63, 17
  3. Liebowitz, 1997, Panic disorder as a chronic illness., J Clin Psychiatry, 58, 5
  4. Zamorski, 2002, What to do when SSRIs fail: eight strategies for optimizing treatment of panic disorder., Am Fam Phys, 66, 1477
  5. Etxebeste, 2000, Olanzapine and panic attacks., Am J Psychiatry, 157, 659, 10.1176/appi.ajp.157.4.659-a · DOI
  6. Khaldi, 2003, Usefulness of olanzapine in refractory panic attacks., J Clin Psychopharmacol, 23, 100, 10.1097/00004714-200302000-00015 · DOI
  7. Chao, 2004, Olanzapine augmentation in panic disorder: a case report., Pharmacopsychiatry, 37, 239, 10.1055/s-2004-832600 · DOI
  8. Doyle, 2003, Establishment of remission criteria for anxiety disorders., J Clin Psychiatry, 64, 40
  9. Koran, 2000, Olanzapine augmentation in treatment-refractory obsessive-compulsive disorder., J Clin Psychiatry, 61, 514, 10.4088/JCP.v61n0709 · DOI · Paper page
  10. Shelton, 2001, A novel augmentation strategy for treating refractory major depression., Am J Psychiatry, 158, 131, 10.1176/appi.ajp.158.1.131 · DOI · Paper page
  11. D'Amico, 2003, Olanzapine augmentation of paroxetine-refractory obsessive-compulsive disorder., Prog Neuro-Psychopharmacol Biol Psychiatry, 27, 619, 10.1016/S0278-5846(03)00050-2 · DOI
  12. Weimer, 2002, Augmentation of selective serotonin reuptake inhibitors (SSRI) with atypical antipsychotics in the treatment of depression., Fortschr Neurol Psychiatr, 70, 210, 10.1055/s-2002-24644 · DOI
  13. Gorman, 2000, Neuroanatomical hypothesis of panic disorder, revised., Am J Psychiatry, 157, 493, 10.1176/appi.ajp.157.4.493 · DOI · Paper page
  14. Spina, 2001, Newer antipsychotics: comparative review of drug interactions., Exp Rev Neurother, 1, 171, 10.1586/14737175.1.2.171 · DOI
  15. Prior, 2003, Interactions between the cytochrome P450 system and the second-generation antipsychotics., J Psychiatry Neurosci, 28, 99
  16. Weigmann, 2001, Fluvoxamine but not sertraline inhibits the metabolism of olanzapine: evidence from a therapeutic drug monitoring service., Ther Drug Monit, 23, 410, 10.1097/00007691-200108000-00015 · DOI
  17. Mathew, 2001, Management of treatment-refractory panic disorder., Psychopharmacol Bull, 35, 97
  18. Birmaher, 2002, Is bipolar disorder specifically associated with panic disorder in youths?, J Clin Psychiatry, 63, 414, 10.4088/JCP.v63n0507 · DOI · Paper page
  19. Soutullo, 1999, Olanzapine in the treatment of adolescent acute mania: a report of seven cases., J Affect Disord, 53, 279, 10.1016/S0165-0327(98)00119-0 · DOI

Cited by

See all 68

Metadata

Authors
Sepede, G., De Berardis, D., Gambi, F., Campanella, D., La Rovere, R., D'Amico, M., Cicconetti, A., Penna, L., Peca, S., Carano, A., Mancini, E., Salerno, R. M., & Ferro, F. M.
Venue
Journal of Clinical Psychopharmacology
Published
2006-02
Volume
26
Issue
1
Pages
45-49
ISSN
0271-0749 (ISSN-L)
OpenAlex
W1970620032
Cited by
68
References
2
FWCI
7.26
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Olanzapine Augmentation in Treatment-Resistant Panic Disorder: A 12-Week, Fixed-Dose, Open-Label Trial. https://app.cochat.ai/papers/10.1097/01.jcp.0000195108.01898.17
The paper
Sepede, G., De Berardis, D., Gambi, F., Campanella, D., La Rovere, R., D'Amico, M., Cicconetti, A., Penna, L., Peca, S., Carano, A., Mancini, E., Salerno, R. M., & Ferro, F. M. (2006). Olanzapine Augmentation in Treatment-Resistant Panic Disorder: A 12-Week, Fixed-Dose, Open-Label Trial. Journal of Clinical Psychopharmacology. https://doi.org/10.1097/01.jcp.0000195108.01898.17

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.